CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Prognostic for the Management of Chronic Lymphocytic Leukemia

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group’s subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation of the first of its HemeScanTM suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests. The test is designed to detect prognostic markers in chronic lymphocytic leukemia (CLL) and is now available to the clinical community through both routine clinical sample processing as well as through CMDX’s innovative Technical Only Program for reference laboratories. This array is the industry’s first clinically validated cancer diagnostic based on BAC array CGH.
MORE ON THIS TOPIC